logo-loader
viewCo-Diagnostics

Full interview: Co-Diagnostics finalizes its own unique Coronavirus detection test

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company has completed the principle design work for a genetic screening test to detect the deadly Wuhan coronavirus.

Egan says the test was developed using the Salt Lake City company’s PCR-based Co-Primer technology, which was recently represented at the International Plant & Animal Genome XXVIII in San Diego.

Quick facts: Co-Diagnostics

Price: 3.05 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $75.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

15 hours ago

2 min read